Santaris Pharma this week announced that it has formed a world-wide drug discovery alliance with Bristol-Myers Squibb.

Under the terms of the deal, the companies will discover and develop drugs against undisclosed targets using Santaris’ locked nucleic acid technology.

Santaris will receive a $10 million upfront payment, and stands to receive an additional $90 million in milestones and funding. Santaris is also eligible for royalties on the sale of products resulting from the arrangement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.